Regeneron 1331 Kinetics Sub-Study HoFH

NCT ID: NCT04722068

Last Updated: 2021-05-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-07
• Study Completion Date: 2021-01-01

Brief Summary

To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.

Detailed Description

Subjects enrolled in the R1500-CL-1331 clinical trial (NCT0226595) will participate in a study visit before and after administration of the ANGPTL3 inhibitor REGN1500, evinacumab) for the evaluation of its effect on lipoprotein kinetics.

Conditions

Hypercholesterolemia, Familial

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial

Group Type: EXPERIMENTAL

Kinetics test

Intervention Type: OTHER

Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.

Interventions

Kinetics test

Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.

Intervention Type: OTHER

Eligibility Criteria

Exclusion Criteria

Inclusion:

• Men and women 18 years or older at the time of the screening visit
• Diagnosis of HoFH by one of the following:

1. Documented mutation or mutations in both LDLR alleles

2. Documented presence of homozygous or compound heterozygous mutations in Apo B and/or PCSK9

3. Documented skin fibroblast LDLR activity <20% of normal

• Willing to consistently maintain his/her usual diet for the duration of the study
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent

Exclusion:

• Background medical LMT (if applicable) that has not been stable for at least 4 weeks (6 weeks for fibrates) prior to the screening visit (week -2) (unless participating in the run-in period to stabilize)
• Having undergone lipid apheresis within 4 weeks prior to the screening visit (week -2) (unless participating in the run-in period to wash out)
• Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins. Note: Patients on thyroid replacement therapy can be included if the dosage of thyroxine has been stable for at least 12 weeks prior to screening visit (week -2)
• Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regiment for at least 6 weeks prior to the screening visit (week -2) Note: Topical, intra-articular, nasal, inhaled, and ophthalmic steroid therapies are not considered as "systemic" and are allowed
• History of a myocardial infarction, unstable angina leading to hospitalization, coronary bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the screening visit (week -2)
• Known history of HIV and a CD4 count less than 350c/mL Note: Patients with a history of HIV can be included, as long as they:

1. have a CD4 count greater than 350c/mL;

2. have an undetectable viral load for at least 12 months prior to screening;

3. have no opportunistic infections or active tuberculosis for at least 12 months prior to screening;

4. are not receiving prophylaxis for opportunistic infections; and have been on stable antiretroviral therapy for at least 12 months prior to screening

• Use of another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer) prior to screening visit (week -2). Includes patients who were involved in a prior clinical trial and are not sure of their treatment assignment.
• Previous participation in any clinical trial of REGN1500
• Conditions/situation such as:

1. Any clinically significant abnormality identified at the time of screening that, in the judgement of the investigator or any subinvestigator, would preclude safe completion of the study or constrain endpoints assessment; eg. major systemic diseases, patients with short life expectancy

2. Patient considered by the investigator or any subinvestigator as inappropriate for this study for any reason, eg: deemed unable to meet specific protocol requirements, such as scheduled visits. Deemed unable to tolerate injections as per the patient or the investigator. Investigator or any subinvestigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol, etc. Presence of any other conditions (eg, geographic or social), either actual or anticipated, that the investigator feels would restrict or limit the patient's participation for the duration of the study

• Laboratory findings during screening period:

1. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody

2. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women of childbearing potential

3. Triglycerides greater than 400 mg/dL ( >3.95 mmol/L) (1 repeat lab is allowed)

4. Estimated glomerular filtration rate <30 mL/min/1.73m^2 according to 4-variable Modification of Diet in Renal Disease Study equation (calculated by central lab)

5. Alanine amintransferase (ALT) or aspartate aminotransferase (AST) >3 x the upper limit of normal (ULN) (1 repeat lab is allowed)

6. Creatine phosphokinase (CPK) >3 x ULN (1 repeat lab is allowed)

• Known hypersensitivity to monoclonal antibody therapeutics
• History of hypersensitivity reaction to doxycycline or similar compound
• Pregnant or breast-feeding women
• Sexually active men, or women of childbearing potential, who are unwilling to utilize adequate contraception for at least 6 months after the last dose of study drug.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marina Cuchel, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Department of Vascular Medicine Amsterdam UMC

Amsterdam, AZ, Netherlands

Countries

United States; Netherlands

References

Reeskamp LF, Millar JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, Gipe DA, Rader DJ, Dallinga-Thie GM, Hovingh GK, Cuchel M. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1753-1759. doi: 10.1161/ATVBAHA.120.315204. Epub 2021 Mar 11.

Reference Type: DERIVED

PMID: 33691480 (View on PubMed)

Other Identifiers

1331-Kin

Identifier Type: -

Identifier Source: org_study_id